Back

An Optimized RNF126-Targeting Covalent Handle for Molecular Glue Degraders

Modi, A.; Toriki, E. S.; Stieger, C. E.; Lau, E. A.; Song, C.; Chew, A.; Tsao, A.; Nishikawa, K.; McKenna, J.; Nomura, D. K.

2026-03-07 biochemistry
10.64898/2026.03.06.709959 bioRxiv
Show abstract

Molecular glue degraders represent a powerful modality for targeting proteins that are refractory to traditional inhibition. However, rational design principles for molecular glue degraders remain poorly defined. Previously, we reported a chemistry-centric strategy to identify covalent degradative handles that, when appended to established ligands, convert non-degradative inhibitors into molecular glue degraders by engaging permissive E3 ligases. This effort identified a fumarate-based electrophilic handle that covalently modified the E3 ligase RNF126, enabling degradation of multiple protein targets when transplanted across diverse ligands. Despite its conceptual impact, the high intrinsic reactivity and cytotoxicity of the fumarate handle limited its translational utility. Here, we report the development of an optimized and metabolically stabilized RNF126-targeting covalent handle incorporating a trans-cyclobutane linker that exhibits reduced glutathione reactivity and diminished cytotoxicity while retaining robust degradative activity. When appended to the BET bromodomain inhibitor JQ1, this optimized handle yielded a potent and selective BRD4 degrader whose activity was dependent on RNF126. Importantly, transplantation of this handle onto a previously non-inhibitory ligand targeting the androgen receptor (AR) and its truncation variant, AR-V7, enabled selective degradation of both AR and AR-V7 in androgen-independent prostate cancer cells, thereby robustly inhibiting AR transcriptional activity beyond the established AR antagonist enzalutamide. Collectively, these findings demonstrate an optimized RNF126-based covalent handle for the rational development of molecular glue degraders against transcriptional regulators, including undruggable variants such as AR-V7.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Journal of the American Chemical Society
199 papers in training set
Top 0.1%
27.7%
2
ACS Central Science
66 papers in training set
Top 0.1%
10.1%
3
Nature Chemical Biology
104 papers in training set
Top 0.1%
10.1%
4
Cell Chemical Biology
81 papers in training set
Top 0.3%
6.4%
50% of probability mass above
5
Nature Communications
4913 papers in training set
Top 28%
6.4%
6
ACS Chemical Biology
150 papers in training set
Top 0.4%
4.0%
7
Angewandte Chemie International Edition
81 papers in training set
Top 0.8%
4.0%
8
Nature Chemistry
34 papers in training set
Top 0.1%
3.6%
9
JACS Au
35 papers in training set
Top 0.2%
2.7%
10
Advanced Science
249 papers in training set
Top 8%
2.1%
11
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 27%
2.1%
12
ACS Medicinal Chemistry Letters
16 papers in training set
Top 0.3%
1.7%
13
Journal of Medicinal Chemistry
68 papers in training set
Top 0.7%
1.7%
14
Chemical Science
71 papers in training set
Top 0.9%
1.7%
15
RSC Chemical Biology
32 papers in training set
Top 0.2%
1.5%
16
Bioorganic & Medicinal Chemistry Letters
10 papers in training set
Top 0.2%
1.1%
17
Acta Pharmaceutica Sinica B
11 papers in training set
Top 0.7%
0.9%
18
Nucleic Acids Research
1128 papers in training set
Top 17%
0.7%
19
eLife
5422 papers in training set
Top 59%
0.7%
20
Science
429 papers in training set
Top 21%
0.6%
21
ChemBioChem
50 papers in training set
Top 1%
0.6%